ARCUS BIOSCIENCES INC (RCUS) Forecast, Price Target & Analyst Ratings

NYSE:RCUS • US03969F1093

21.97 USD

-0.73 (-3.22%)

At close: Mar 13, 2026

21.97 USD

0 (0%)

After Hours: 3/13/2026, 8:04:00 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARCUS BIOSCIENCES INC (RCUS).

Consensus Price Target

Price Target

$32.95

+ 49.96% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 4, 2026
Period: Q1 / 2026
EPS Estimate: -$0.98
Revenue Estimate: 27.497M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

81.11%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$32.95

Upside

+ 49.96%

From current price of $21.97 to mean target of $32.95, Based on 18 analyst forecasts

Low

$20.20

Median

$31.62

High

$49.35

Price Target Revisions

1 Month

-2.12%

3 Months

-7.98%

Price Target Summary

18 Wall Street analysts provided a forecast for the next 12 months for RCUS. The average price target is 32.95 USD. This implies a price increase of 49.96% is expected in the next year compared to the current price of 21.97.

The average price target has been revised downward by 7.98% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

81.11%

RCUS was analyzed by 18 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about RCUS.

In the previous month the buy percentage consensus was at a similar level.

RCUS was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-03-05	Citigroup	Maintains	Buy -> Buy
2026-03-02	Leerink Partners	Maintains	Outperform -> Outperform
2026-03-02	HC Wainwright & Co.	Reiterate	Buy -> Buy
2026-02-12	Wells Fargo	Downgrade	Overweight -> Equal-Weight
2026-01-13	Goldman Sachs	Upgrade	Neutral -> Buy
2026-01-08	Morgan Stanley	Downgrade	Overweight -> Equal-Weight
2025-12-12	HC Wainwright & Co.	Maintains	Buy -> Buy
2025-11-28	B of A Securities	Maintains	Neutral -> Neutral
2025-10-30	Goldman Sachs	Maintains	Neutral -> Neutral
2025-10-29	Citigroup	Maintains	Buy -> Buy
2025-10-29	HC Wainwright & Co.	Maintains	Buy -> Buy
2025-10-20	Wells Fargo	Maintains	Overweight -> Overweight
2025-10-13	Citigroup	Maintains	Buy -> Buy
2025-10-07	Truist Securities	Reiterate	Buy -> Buy
2025-08-07	Wells Fargo	Maintains	Overweight -> Overweight
2025-05-09	Morgan Stanley	Maintains	Overweight -> Overweight
2025-05-08	Goldman Sachs	Maintains	Neutral -> Neutral
2025-05-07	Wells Fargo	Maintains	Overweight -> Overweight
2025-04-23	Barclays	Maintains	Overweight -> Overweight
2025-02-26	HC Wainwright & Co.	Upgrade	Neutral -> Buy
2025-02-19	B of A Securities	Maintains	Neutral -> Neutral
2025-02-18	Morgan Stanley	Maintains	Overweight -> Overweight
2025-02-18	HC Wainwright & Co.	Maintains	Neutral -> Neutral
2024-11-06	HC Wainwright & Co.	Reiterate	Neutral -> Neutral
2024-10-25	Barclays	Maintains	Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 4, 2026
Period: Q1 / 2026
EPS Estimate: -$0.98
Revenue Estimate: 27.497M
Revenue Q2Q: -1.80%
EPS Q2Q: 14.23%
Number of Analysts: 10

Next Earnings Revisions

Revenue (1 Month)

30.42%

Revenue (3 Months)

-14.15%

EPS (1 Month)

14.03%

EPS (3 Months)

13.38%

Next Earnings Summary

RCUS is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.98 USD and the consensus revenue estimate is 27.50M USD.

The next earnings revenue estimate has been revised downward by 14.15% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth	117M 4.46%	258M 120.51%	247M -4.26%	99.296M -59.80%	156.23M 57.34%	231.09M 47.92%	517.37M 123.88%	995.6M 92.43%	1.458B 46.44%	2.028B 39.09%	2.486B 22.58%
EBITDA YoY % growth	-332M -21.17%	-300M 9.64%	-376M -25.33%	-465.936M -23.92%	-393.27M 15.60%	-171.845M 56.30%	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-340M -21.43%	-310M 8.82%	-386M -24.52%	-474.678M -22.97%	-442.601M 6.76%	-226.266M 48.88%	-112.556M 50.25%	179.09M 259.11%	395.1M 120.62%	657.33M 66.37%	904.24M 37.56%
Operating Margin	-290.60%	-120.16%	-156.28%	-478.04%	-283.30%	-97.91%	-21.76%	17.99%	27.10%	32.41%	36.37%
EPS YoY % growth	-4.15 -11.56%	-3.10 25.30%	-3.30 -6.45%	-4.24 -28.50%	-3.41 19.60%	-2.46 27.85%	-0.94 61.71%	0.70 174.37%	2.54 263.33%	3.70 45.49%	4.82 30.30%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26	Q1 / 27	Q2 / 27	Q3 / 27	Q4 / 27	Q1 / 28	Q2 / 28	Q3 / 28
EPS Q2Q % growth	-0.98 14.23%	-1.06	-1.06 16.74%	-1.04 -17.13%	-0.98 -0.46%	-0.97 8.85%	-0.87 18.10%	-0.80 23.48%	-0.52 46.83%	-0.32 67.09%	-0.20 77.27%
Revenue Q2Q % growth	27.497M -1.80%	24.693M -84.57%	24.959M -4.00%	21.586M -34.59%	30.173M 9.73%	21.478M -13.02%	38.356M 53.68%	52.416M 142.82%	106.13M 251.74%	149.99M 598.34%	178.76M 366.05%
EBITDA Q2Q % growth	-114.966M 3.39%	-124.562M -4,052.06%	-144.451M -7.00%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-117.902M 3.36%	-128.679M -1,508.49%	-116.851M 17.71%	-109.803M 3.68%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

7.86%

EPS Next 5 Year

17.21%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

-2.78%

Revenue Next 5 Year

31.68%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

16.06%

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ARCUS BIOSCIENCES INC / RCUS Forecast FAQ

What is the average price target for ARCUS BIOSCIENCES INC (RCUS) stock?

18 analysts have analysed RCUS and the average price target is 32.95 USD. This implies a price increase of 49.96% is expected in the next year compared to the current price of 21.97.

What is the next earnings date for RCUS stock?

ARCUS BIOSCIENCES INC (RCUS) will report earnings on 2026-05-04, after the market close.

What are the consensus estimates for RCUS stock next earnings?

The consensus EPS estimate for the next earnings of ARCUS BIOSCIENCES INC (RCUS) is -0.98 USD and the consensus revenue estimate is 27.50M USD.

How many analysts cover ARCUS BIOSCIENCES INC (RCUS) stock?

The number of analysts covering ARCUS BIOSCIENCES INC (RCUS) is 18.

Analyst forecast overview

Forecast Snapshot